Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BIOTRONIK Home Monitoring® Reduces Inappropriate ICD Shocks by 52%

Published: Friday, December 21, 2012
Last Updated: Friday, December 21, 2012
Bookmark and Share
ECOST trial results published in European Heart Journal.

BIOTRONIK has announced that the European Heart Journal has published the clinical results of the ECOST trial (Effectiveness and Cost Of ICD Follow-Up Schedule with Telecardiology).

The randomized controlled study evaluated the safety and efficacy of BIOTRONIK Home Monitoring® compared with standard in-office follow-up visits for patients with implantable cardioverter-defibrillators (ICDs).

Results from ECOST provide pioneering scientific evidence that continuous remote monitoring with BIOTRONIK Home Monitoring® reduces inappropriate shocks, may improve battery longevity in long-term follow-up of patients implanted with an ICD and is as safe as, sometimes even safer than standard in-office follow-ups. This outcome is consistent with previous findings from studies such as the landmark TRUST trial.

ECOST is a prospective multicenter clinical trial designed to examine the safety and efficacy of remote monitoring of ICD patients with BIOTRONIK Home Monitoring® over 27 months.

The study analyzed 433 patients from 43 sites throughout France who were randomly assigned to home monitoring follow-up or standard in-office care.

The 221 home monitoring patients (the active group) were seen in the ambulatory department once per year, unless home monitoring reported a technical or clinical event requiring an in-office visit. The 212 control group patients underwent in-office visits every six months.

During a two-year period, the overall number of delivered shocks in the home monitoring group were 71% lower than in the control group-a significant decrease.

Furthermore, the proportion of patients who received inappropriate shocks was 52% lower in the home monitoring group than in the control group.

While some remote monitoring technologies can drain the device battery in the long term, daily BIOTRONIK Home Monitoring® retains ICD battery life: ECOST showed a 76% reduction in the number of capacitor charges for the BIOTRONIK Home Monitoring® group (499 vs. 2081), resulting in extended device longevity.

“The ECOST trial results prove BIOTRONIK Home Monitoring® reduces inappropriate shocks in patients and also positively extends the ICD’s battery longevity,” said Professor Salem Kacet, principal investigator of the ECOST study.

Professor Kacet continued, “This advanced technology is very important for the observation of arrhythmias and early adaptation of ICD therapy. Patients benefit from the reduced risk of inappropriate shocks-which can be a very unpleasant experience-and need ICD replacement less frequently.”

“Developing safe, innovative, effective therapies to improve patient health is BIOTRONIK’s number one priority,” said Christoph Böhmer, President International of BIOTRONIK.

Böhmer continued, “By conducting landmark trials like ECOST, we are providing definitive answers to questions and challenges physicians face in their practices. In addition, we are making significant contributions to the field of cardiac rhythm therapy research. BIOTRONIK Home Monitoring® enhances the patient’s quality of life and simplifies patient treatment.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BIOTRONIK Orsiro Hybrid DES Lives Up to Abbott’s XIENCE PRIME™
Positive 9 month results from BIOFLOW-II clinical trial and 12 month results from BIOFLOW-III registry presented at EuroPCR congress.
Tuesday, July 09, 2013
BIOTRONIK Announces 12-Month Results from 4EVER Study
Results show strong evidence of benefits for lower limb intervention when using Pulsar stents.
Monday, November 19, 2012
First CRT-D Patient Enrolled in the EuroEco ICD/CRT-D Trial
Study to assess the economic effects of BIOTRONIK Home Monitoring®.
Tuesday, July 24, 2012
Large-Scale BIOTRONIK SPIRIT-ICD Study Enrollment Complete
SPIRIT-ICD study explores benefits of intensified diagnostic follow-up and timely therapeutic intervention for high-risk patient group.
Monday, July 09, 2012
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!